Asia FX muted, dollar weakens slightly ahead of Fed rate decision
On Tuesday, Cantor Fitzgerald reaffirmed its Overweight rating on shares of Arcturus Therapeutics (NASDAQ:ARCT), currently trading at $11.59. Following the company’s release of its first-quarter financial results for 2025, the firm updated its model to account for the actual earnings reported. Arcturus Therapeutics disclosed a net loss of $0.52 per basic share for the quarter. According to InvestingPro data, analysts maintain a strong buy consensus on the stock, with price targets ranging from $44 to $140.
The update to Cantor Fitzgerald’s model includes the latest operating expenses incurred by Arcturus Therapeutics, as well as the firm’s projected operating expenses for the company. These adjustments have led to revised estimates for the company’s earnings per share (EPS). InvestingPro analysis reveals that while the company maintains a solid current ratio of 5.64, indicating strong short-term liquidity, three analysts have recently revised their earnings estimates downward for the upcoming period.
Arcturus Therapeutics is a biotechnology firm focused on the discovery, development, and commercialization of RNA medicines for various diseases. The company’s financial performance, particularly its earnings and operational costs, are closely watched by investors and analysts as indicators of its potential growth and financial health. InvestingPro data shows the company holds more cash than debt on its balance sheet, though it’s currently experiencing negative gross profit margins of -22.83%.
The Overweight rating suggests that Cantor Fitzgerald’s analysts believe Arcturus’ stock has the potential to outperform the average return of the stocks in the analyst’s coverage universe over the next 12 to 18 months. The rating is based on the firm’s analysis of the company’s earnings and operational efficiency.
Investors often rely on ratings from research firms like Cantor Fitzgerald to make informed decisions about buying or selling stocks. Such ratings are based on thorough research and analysis of a company’s financials, market position, and growth prospects.
Arcturus Therapeutics’ latest earnings report and the subsequent rating reaffirmation by Cantor Fitzgerald are significant for current and potential shareholders, providing insight into the company’s financial trajectory and the research firm’s outlook on the stock’s performance.
In other recent news, Arcturus Therapeutics reported a significant revenue shortfall in its first-quarter 2025 financial results, with revenue at $29.4 million, missing the anticipated $205.21 million. The company also posted an earnings per share loss of $0.52, which fell short of the forecasted profit of $3.59. Despite these challenges, Arcturus has extended its cash runway to the first quarter of 2028. Analyst firms have weighed in on these developments, with Canaccord Genuity maintaining a Buy rating but lowering its price target to $66, and Citi also retaining a Buy rating with a $44 target. Arcturus has strategically decided to focus on its cystic fibrosis (CF) and Ornithine Transcarbamylase (OTC) deficiency programs, halting certain early-stage vaccine efforts. Upcoming data readouts for these programs are expected in mid-2025. The company continues to progress with its H5N1 and seasonal influenza vaccine projects. These recent developments underscore Arcturus’s strategic focus on its mRNA therapeutics pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.